title: Response.
authors.forename: Ulaş
authors.initials: U
authors.lastname: Yener
authors.forename: Timucin
authors.initials: T
authors.lastname: Avsar
authors.forename: Emel
authors.initials: E
authors.lastname: Akgün
authors.forename: Aşkın
authors.initials: A
authors.lastname: Şeker
authors.forename: Yaşar
authors.initials: Y
authors.lastname: Bayri
authors.forename: Türker
authors.initials: T
authors.lastname: Kılıç
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D003315:Cornea; D003390:Cranial Nerve Neoplasms / Q000098:blood supply*; D006801:Humans; D008297:Male; D009389:Neovascularization, Pathologic / Q000188:drug therapy*; D009464:Neuroma, Acoustic / Q000098:blood supply*; D010879:Piperazines / Q000627:therapeutic use*; D011743:Pyrimidines / Q000627:therapeutic use*; D023041:Xenograft Model Antitumor Assays
chemical_list: D000970:Antineoplastic Agents; D010879:Piperazines; D011743:Pyrimidines